Trials
5 active
6 in total · 6 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Patients will receive intratumoral administrations into injectable cutaneous, subcutaneous, and nodal tumors of Daromun once weekly for up to 4 weeks.”In the company’s words, NCT03567889 on ClinicalTrials.gov
- Tested for
- Locally Advanced Basal Cell Carcinoma (2 trials), Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID, Melanoma Stage III, Melanoma Stage IV, Locally Advanced Cutaneous Squamous Cell Carcinoma
- Main trialPhase 3
- “The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with respect to the standard of care (surgery and adjuvant therapy).”In the company’s words, NCT03567889 on ClinicalTrials.gov
- Other names
- Daromun · bifikafusp alfa/onfekafusp alfa
Other drugs for Locally Advanced Basal Cell Carcinoma
- BO-112Highlight Therapeutics · Phase 2
- STAR0602Marengo Therapeutics, Inc. · Phase 1/2
- MDNA11Medicenna Therapeutics, Inc. · Phase 1/2
- PembrolizumabMerck & Co. · Phase 1/2
- Vusolimogene OderparepvecReplimune, Inc. · Phase 1/2
- CemiplimabRegeneron · Phase 2
Coming up5
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- Jul 2028Phase 2 trial completes · ClinicalTrials.gov
- Feb 2031Phase 2 trial completes · ClinicalTrials.gov
- Feb 2031Phase 2 trial completes · ClinicalTrials.gov
- Feb 2031Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Dec 2027 | Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients | |
| Phase 2Recruiting | Jul 2028 | Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients | |
| Phase 2Recruiting | Feb 2031 | L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) | |
| Phase 2Recruiting | Feb 2031 | L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma | |
| Phase 2Recruiting | Feb 2031 | L19IL2/TNF in Patients With Basal Cell Carcinoma | |
| Phase 2Unknown | Jun 2024 | L19IL2/L19TNF in Skin Cancer Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026